Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2420 January 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Trastuzumab deruxtecan		
Initial application Applications Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate) Patient is currently on treatment with trastuzumab deruxtecan and met all remaining criteria prior to commencing treatment Patient has metastatic breast cancer expressing HER-2 IHC3+ or ISH+ (including FISH or other current technology) Patient has previously received trastuzumab and chemotherapy, separately or in combination The patient has received prior therapy for metastatic disease or The patient developed disease recurrence during, or within six months of completing adjuvant therapy and Patient has a good performance status (ECOG 0-1) and Patient has not received prior funded trastuzumab deruxtecan treatment and Treatment to be discontinued at disease progression		
Renewal Current approval Number (if known):		
Prerequisites(tick boxes where appropriate)		
The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab deruxtecan and Treatment to be discontinued at disease progression		
Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.		